Incidence and treatment of malignant tumors of the genitourinary tract in renal transplant recipients.

Autor:	Ochoa-López JM; Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México., Gabilondo-Pliego B; Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México., Collura-Merlier S; Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México., Herrera-Cáceres JO; Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México., de Zavaleta MS; Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México., Rodríguez-Covarrubias FT; Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México., Feria-Bernal G; Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México., Gabilondo-Navarro F; Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México., Castillejos-Molina RA; Department of Urology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México.
Jazyk:	angličtina
Zdroj:	International braz j urol : official journal of the Brazilian Society of Urology [Int Braz J Urol] 2018 Sep-Oct; Vol. 44 (5), pp. 874-881.
DOI:	10.1590/S1677-5538.IBJU.2017.0471
Abstrakt:	Purpose: To provide data of the incidence and management of common urological malignancies in renal transplant recipients. Materials and Methods: We conducted a retrospective analysis of a prospective database from August 1967 to August 2015. A descriptive analysis of the sample was performed. Results: Among 1256 consecutive RTR a total of 88 patients developed malignancies (7%). There were 18 genitourinary tumors in the 16 patients (20.45% of all malignant neoplasms), incidence of 1.27%. The most common neoplasm encounter was renal cancer (38.8%), followed by urothelial carcinoma (33.3%). Median follow up of transplantation was 197 months (R, 36-336). Mean time from RT to cancer diagnosis 89±70 months (R, 12-276). CsA and AZA was the most common immunosuppression regimen in 68.75%. Mean follow-up after diagnosis was 103±72 months (R 10-215). Recurrence free survival rate of 100%. Overall survival of 89.5% of the sample; there were two non-related cancer deaths during follow up. Conclusions: The incidence of neoplasms in RTR was lower than in other series, with favorable functional and oncologic results after treatment. This suggests that actions to reduce the risk of these malignancies as well as a strict follow-up are mandatory for an early detection and treatment. Competing Interests: Conflict of interest: None declared. (Copyright® by the International Brazilian Journal of Urology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu